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Introduction
Metallothioneins (MT) represent intracellular proteins
of 6-7 kDa molecular weight, widely manifested both
in plant and animal kingdom. They consist of 61-68
amino acids, among which around 30% are cysteine
residues [1,2]. In humans four classes of the proteins
were identified, including MT-1, MT-2, MT-3 and MT-
4, containing the total number of ten functional iso-
forms. Expression of MT-1 and MT-2 manifest vari-
able intensity in all tissues and organs of the body. The
highest concentration of the proteins was detected in
the liver, pancreas, intestine and kidneys [1]. MT-3 and
MT-4 are tissue specific and their expression in normal
conditions is manifested, respectively, in neurons of
central nervous system and in squamous epithelia of
skin and alimentary tract [2,3]. MT-coding genes are
located on chromosome 16q13, and their expression
may be induced by various factors, including heavy
metals, hormones, cytokines, growth factors, organic
compounds and free radicals [4-7]. 
The unique property of MT, which significantly
determines their role in the body, involves the ability
of binding heavy metals ions, such as zinc, copper,
mercury, lead or cadmium. MT are responsible, first of
all, for maintenance of metal homeostasis and detoxi-
cation processes [2,8,9]. Reversible binding of zinc
ions causes that MT affect activity of several zinc-
dependent proteins and enzymes. In this manner MT
control several intracellular processes, including  pro-
liferation, apoptosis and cell differentiation [10].
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Abstract: Our study aimed at examining significance of metallothionein (MT) expression in ductal breast cancers by deter-
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immunohistochemical reactions was measured using the semiquantitative IRS scale of Remmele. Intensity of colour reac-
tions targeted at Ki-67, ER, PgR was evaluated scoring proportions of positive cells, while HER-2-specific reactions were
evaluated in the scale of 0-3 points. The lowest level of MT expression was detected in breast cancer cases of G1 malig-
nancy grade (G1 vs G3 p=0.020). A positive correlation between MT and Ki-67 antigen expression (r=0.32, p=0.019) was
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Moreover, MT, due to high content of cysteine
residues in their molecules exhibit strong anti-oxida-
tive properties. In addition to glutathione and anti-
oxidative enzymes, they constitute one of the principal
elements of cell protection against free radicals and
effects of oxidative stress [3,8].
Studies performed till now demonstrated aug-
mented synthesis of MT in various tumours of either
epithelial or mesenchymatic origin [3,10,11]. It is
suggested that role of the proteins in carcinogenesis
is linked to their involvement in processes of cells
proliferation and differentiation [12,13]. There have
been proposed various mechanisms of MT influence
on proliferation of cells and progression of tumours.
MT provide a direct source of zinc for enzymes
engaged in processes of replication, transcription and
proteins biosynthesis, taking place in intensely pro-
liferating neoplastic cells. This has been confirmed
not only by elevated level of MT in the region of
hyperplasia but also by protein translocation from
cytoplasm to cell nucleus at the phase of DNA syn-
thesis (S phase) in proliferating cells [3,14,15].
Moreover, in in vitro experiments MT was shown to
be capable of controlling zinc ion accessibility and,
in this way, of modulating activity of transcription
factors, including Sp1 and TFIIA, engaged in cell
cycle control [1,10]. Interaction with p53 protein, the
product of a suppressor gene, seems to be very
important for development of a tumour. MT was
demonstrated to be capable of removing zinc ions
from p53 protein molecules, leading to changes in
their spatial structure and inactivation. This, similar-
ly to mutations within p53, results in an uncontrolled
cell proliferation [16-20]. The other suggested mech-
anism by which MT may increase proliferative poten-
tial of neoplastic cells involves their protection from
apoptosis. There was described a specific interaction
of MT with p50 subunit of NF-κB transcription fac-
tor, which results in inhibition of apoptosis [21,22]. 
Our study aimed at examining significance of MT
expression in ductal breast cancers by determination of
a relationship between MT protein (MT-1/2) and
selected prognostic factors, including grade of histo-
logical differentiation (G), expression of Ki-67 prolif-
erative antigen, expression of estrogen receptors (ER)
and progesterone receptors (PgR) and expression of
HER-2 receptor.
Material and methods
Tissues. The investigated material included 54 samples of invasive
ductal breast cancer, obtained from patients subjected to surgery in
the Lower Silesia Centre of Oncology in Wroclaw in 2004-2007.
The mean age of the patients was 63.65±12.84 years. In each case
the diagnosis was confirmed by histopathology. The grade of his-
tological differentiation (G) was estimated according to Bloom-
Richardson scale [23]. The group of studied breast cancers con-
tained highly differentiated tumours (G1) – 11 cases, moderately
differentiated tumours (G2) – 27 cases and poorly differentiated
tumours (G3) – 16 cases.
Immunohistochemistry. Expression of MT (MT-1/2), Ki-67, ER,
PgR and HER-2 was examined immunohistochemically in paraffin
sections. Tumour samples were fixed in 10% buffered formalin,
dehydrated and embedded in paraffin. Four-micrometer sections were
mounted on Superfrost Plus slides (Menzel Gläser, Germany),
dewaxed with xylene and gradually rehydrated. Activity of endoge-
nous peroxidase was blocked using 3% hydrogen peroxide. Immuno-
histochemical reactions were performed using specific antibodies:
MT-specific monoclonal mouse antibody, clone E9 (DakoCytoma-
tion, Denmark) at dilution 1:100, Ki-67-specific monoclonal mouse
antibody, clone MIB-1 (DakoCytomation, Denmark) at dilution
1:100, ER-specific monoclonal mouse antibody, clone 1D5
(DakoCytomation, Denmark) at dilution 1:75, PgR-specific mono-
clonal mouse antibody, clone PgR 636 (DakoCytomation, Denmark)
at dilution 1:100. Incubation with the antibodies was conducted
overnight, at 4°C. Except of the MT-specific reaction, in all remain-
ing cases the sections were boiled in Antigen Retrieval Solution
(DakoCytomation, Denmark). Following incubation with secondary
biotinylated antibodies (Biotinylated Link, DakoCytomation, Den-
mark), reactions with the streptavidin-biotinylated peroxidase com-
plex (LSAB+ System-HRP, DakoCytomation, Denmark) were per-
formed. The peroxidase substrate of 3,3'-diaminobenzidine (DAB+
Chromogen, DakoCytomation, Denmark) was used as a chromogen.
All the sections were counterstained with haematoxylin. Expression
of HER-2 was examined using HercepTest™ kit containing appro-
priate rabbit polyclonal antibody, according to the procedure recom-
mended by the manufacturer (DakoCytomation, Denmark). 
The intensity of MT expression was evaluated using the semi-
quantitative IRS (immuno-reactive score) scale according to Rem-
mele, which took into account the intensity of the colour reaction
and the percentage of positive cells [24]. The final score represent-
ed a product of points given for individual traits and ranged
between 0 and 12 (Table 1). Expression of Ki-67 antigen, estrogen
receptors (ER) and progesterone receptors (PgR) was evaluated
scoring percentage of cells manifesting nuclear colour reaction. In
every case the appraisal was performed in five representative
microscope fields (hot-spots, magnification ×200) using the soft-
ware for computer-assisted image analysis, analySIS 3.2. (Ger-
many). In evaluation of HER-2 receptor expression the scale was
employed which took into account intensity and character of mem-
branous colour reaction and percentage of cells manifesting such a
reaction [25] (Table 2). Intensity of immunohistochemical reactions
was evaluated independently by two pathologists.
Statistical analysis. The obtained results were subjected to statis-
tical analysis using Statistica 7.1 software (StatSoft, Poland). For
normality of the distribution the Kolmogorov-Smirnov test was
employed. Correlation between expression intensities of selected
markers was examined using Spearman rank correlation index.
Significance of differences in expression of studied markers was
examined using U test of Mann-Whitney. The results were regard-
ed statistically significant at p<0.05. 
Results
Expression of metallothionein (MT) was demonstrated
in 53 cases of ductal breast cancer (98.15%). In all the
cases a cytoplasmic or a nuclear-cytoplasmic reaction
was noted (Fig. 1A, 1B). Most of the examined
tumours manifested different distribution of MT and
differences in intensity of the reaction. The mean
intensity of reaction in IRS scale was 4.48±2.72 pts.
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Expression of Ki-67 antigen was detected in all stud-
ied cases. The colour reaction of a variable intensity
manifested the nuclear localization (Fig. 1C). The mean
percentage of positive cells was 41.18%±25.93%. 
Expression of estrogen receptors (ER) was demon-
strated in 40 cases (74.07%) (Fig. 1D). The mean per-
centage of positive cells was 53.35%±40.16%. 
Presence of progesterone receptors (PgR) was doc-
umented in 37 cases (68.52%) (Fig. 1E). The mean
percentage of positive cells was 36.85%±41.50%. 
Expression of HER-2 receptor was detected in 42
cases (77.78%). The colour reaction of a variable
intensity demonstrated a membranous location (Fig.
1F). The mean intensity of the reaction in the applied
scale of appraisal was 1.48±1.06 pts. 
The lowest expression of MT was found in the
highly differentiated breast cancers, G1. In the worse
differentiated breast cancer cases, G2 and G3, the level
of MT was slightly higher and manifested an increas-
ing trend (G1 vs G3, p=0.020) (Fig. 2).
In order to examine the relationship between
expression of MT and other studied markers, Spear-
man's rank correlation index was used. Results of the
analyses demonstrated a moderately positive correla-
tion between expression of MT and Ki-67 antigen
(r=0.32, p=0.019) (Fig. 3). Moreover moderately neg-
ative correlations were detected between MT expres-
sion and expression of ER receptors (r=-0.35,
p=0.008) (Fig. 4) and PgR receptors (r=-0.27,
p=0.046) (Fig. 5). On the other hand, no relationship
could be disclosed between MT expression and
expression of HER-2 (r=0.12, p=0.37).
Discussion
The numerous studies performed up to now demon-
strated increased MT (MT-1/2) expression in several
tumours, including tumours of lungs, ovary, urinary
bladder, large intestine and kidneys [26-30]. In most of
the cases high level of the protein was linked to poor
prognosis. Several authors showed an evident relation-
ship between intensity of MT expression and clinical
advancement of the tumours, frequency of metastasis
development, as well as shortening of survival rate and
disease free survival [17,28,31-34]. In some tumours
also a significant correlation between high levels of
MT and unfavourable results of treatment was
observed [30,35,36]. 
An increased MT (MT-1/2) expression was demon-
strated also in breast cancers, but clinical significance
of the proteins has not been yet unequivocally deter-
mined. In the normal mammary gland MT expression
is noted mainly in myoepithelial cells, while in epithe-
lial cells of ducts MT expression is found very rare
[15]. A similar pattern of MT expression was observed
in the examined benign lesions of mammary gland,
including adenomas, adenofibromas and papillomas
[37]. In lobular breast cancers as well as in other, less
frequent histological types of the tumour, including
mucinous carcinoma and papillary carcinoma, in most
cases no MT expression or weak cytoplasmic reactions
was shown [13,15]. On the other hand, a definitely
increased MT expression was noted in ductal breast
cancer, both in in situ and invasive forms. According
to authors of the till now published reports 26% to
100% of all ductal breast cancer cases manifest over-
expression of MT [15].
It is suggested that the role of MT in carcinogene-
sis and tumour progression could be linked to the
involvement of MT in processes of cell proliferation
and differentiation [10,12,13]. Using flow cytometry,
the highest concentration of MT was found in cells at
the end of G1 phase and at the threshold of G1/S phas-
es [38]. Moreover, a significant MT translocation was
immunocytochemically demonstrated to take place
from cytoplasm to cell nucleus during S phase of cell
cycle [3,15]. In in vitro studies conducted on human
breast cancer cell line MCF-7, the inhibition of MT
expression by anti-sense oligonucleotides was
observed to inhibit cell growth and to activate apopto-
sis [39]. Disturbances in cell cycle linked to uncon-
trolled cell proliferation and inhibition of apoptotic
process are widely known to represent a significant
component of neoplastic progression. The increased
Table 1. Evaluation of MT expression using IRS scale [24]. Table 2. Evaluation of HER-2 receptor expression [25]. 
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proliferative activity results in a more pronounced
expansion of the tumour, in accelerated course of the
disease and, thus, in worse prognosis.
In our investigations we have evaluated expression
of MT (MT-1/2) in cells of ductal breast cancer and its
relationship with an increased proliferative potential of
neoplastic cells, manifested by expression of Ki-67
antigen. Ki-67 antigen is thought to represent one of
the most sensitive indices of cell proliferative activity
and numerous till now conducted studies have corrob-
orated prognostic value of its expression in various
tumours [40]. In the examined cases of invasive ductal
breast cancer we have demonstrated a positive correla-
tion between MT and Ki-67 antigen expression, cor-
roborating the earlier results of Jin et al., obtained in
the same type of tumour [41]. A similar relationship
has been documented, i.a., in squamocellular
oesophageal carcinoma, nasopharyngeal carcinoma, as
well as in cancers of ovary, large intestine and kidneys
[27,29,30,32,42]. Positive correlation between MT and
Fig. 1. Expression of studied proteins in cells of ductal breast cancers. MT, a weak nuclear-cytoplasmic reaction (A). MT, moderate nuclear-
cytoplasmic reaction (B). Ki-67, moderate nuclear reaction (C). ER, strong nuclear reaction (D). PgR, strong nuclear reaction (E). HER-2,
strong membranous reaction (F). Immunohistochemical technique, counterstained with hematoxylin (original magnification ×200).
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Ki-67 expression has been confirmed also in tumours
of mesodermal origin, i.e. in histiocytic fibrosarcoma,
adiposarcoma and synovial sarcoma [43]. Results of
our studies as well as reports of other authors corrobo-
rate the hypothesis on involvement of MT in process-
es linked to cell proliferation.
The involvement of MT in processes of tumour dif-
ferentiation, proliferation and progression is also indi-
cated by the relationship between expression levels of
the proteins and tumour grade of histological differen-
tiation (G). The grade of histological differentiation or,
in other words, grade of malignancy is a resultant of
three tumour characteristics, including the ability to
form glandular structures, polymorphism of cells
which form tumour structures and mitotic activity. Jin
et al. found that in breast cancer cases of the highest
malignancy G3, expression of MT was significantly
higher than in better differentiated cases, G1 and G2
[41,44]. Similar observations were made recently by
Yap et al. [36]. In turn, Gallicchio et al. in the studied
group of 110 cases of ductal breast cancer demonstrat-
ed a strong positive correlation between intensity of
MT expression and grade of malignancy [45]. Our
results have corroborated results of other authors: we
have noted a clearly lower expression of MT in cases
of a lower malignancy grade G1, and the expression
has increased with increasing grade of cancer malig-
nancy. 
Analysis of the obtained results demonstrated also
negative correlation between MT expression on one
hand and expression of estrogen (ER) and proges-
terone (PgR) receptors on the other. Presence of ER
and PgR in cells of breast cancer and other hormone-
dependent tumours, including ovarian and uterine can-
Fig. 2. Intensity of MT expression (IRS) in ductal breast cancers
as related to their grade of histological differentiation, G
(*p=0.020 G1 vs G3).
Fig. 4. Correlation between expression of MT (IRS) and expres-
sion of ER receptor (% cells) in the studied group of ductal breast
cancers (r=-0.35, p=0.008).
Fig. 3. Correlation between expression of MT (IRS) and expres-
sion of Ki-67 antigen (% cells) in the studied group of ductal breast
cancers (r=0.32, p=0.019).
Fig. 5. Correlation between expression of MT (IRS) and expres-
sion of PgR receptor (% cells) in the studied group of ductal breast
cancers (r=-0.27, p=0.046).
cers, is linked to a more favourable prognosis. The
estrogen-positive cases of mammary cancers have
been shown to manifest lower proliferative potential
and lower expression of receptors for epidermal
growth factors, such as EGFR and HER-2 [46,47]. The
increased expression of MT in cases of breast cancers
devoid of estrogen and progesterone receptors con-
firms the unfavourable prognostic significance of the
proteins. Results of our studies corroborate reports of
other authors. Ioachim et al. observed that in ductal
breast cancers MT expression is significantly higher in
cases characterized by absence of ER and PgR [48,49].
The same authors in endometrial carcinoma showed an
evident negative correlation between intensity of MT
expression and contents of ER and PgR [50]. In turn,
in ovarian cancers no relationship between expression
of MT and status of receptors for steroid hormones
was demonstrated [27].
On the other hand, in the examined group of ductal
breast cancers no relationships could have been detect-
ed between expression of MT and HER-2 receptor,
belonging to the family of membranous epidermal
growth factor receptors (EGFR). Cases of breast can-
cer with over-expression of HER-2 receptor are char-
acterized by a more aggressive course and less
favourable prognosis [25]. In the available references
no data could have been noted on relationships
between MT and HER-2, which would allow to verify
the result obtained in this study.
The conducted studies indicate that pronounced
expression of MT protein in ductal breast cancers may
represent an unfavourable prognostic index. Results of
this report as well as data of other authors suggest a
need for continuing studies which will permit to better
understand role of MT in the neoplastic process and to
define clinical significance of their expression in vari-
ous types of tumours, including breast cancer.
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